Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Stefan A. Koerber; Manuel Röhrich; Leon Walkenbach; Jakob Liermann; Peter L. Choyke; Christoph Fink; Cathrin Schroeter; Anna-Maria Spektor; Klaus Herfarth; Thomas Walle; Jeremie Calais; Hans-Ulrich Kauczor; Dirk Jaeger; Juergen Debus; Uwe Haberkorn; Frederik L. Giesel

doi:10.2967/jnumed.123.266046

Research ArticleClinical Investigation

Open Access

Impact of ⁶⁸Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Stefan A. Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L. Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, Jeremie Calais, Hans-Ulrich Kauczor, Dirk Jaeger, Juergen Debus, Uwe Haberkorn and Frederik L. Giesel

Journal of Nuclear Medicine November 2023, 64 (11) 1712-1720; DOI: https://doi.org/10.2967/jnumed.123.266046

Stefan A. Koerber

1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;

2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;

3Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany;

4Department of Radiation Oncology, Barmherzige Brueder Hospital Regensburg, Regensburg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Manuel Röhrich

5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

6Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Leon Walkenbach

1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jakob Liermann

1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;

2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter L. Choyke

7Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christoph Fink

1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;

2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Cathrin Schroeter

5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anna-Maria Spektor

5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Klaus Herfarth

1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;

2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;

3Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Walle

8Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany;

9Clinical Cooperation Unit Virotherapy, German Cancer Research Center, Heidelberg, Germany;

10German Cancer Consortium, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jeremie Calais

11Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hans-Ulrich Kauczor

12Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dirk Jaeger

6Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Juergen Debus

1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;

2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;

3Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany;

10German Cancer Consortium, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Uwe Haberkorn

5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

13Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frederik L. Giesel

5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

8Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany;

14Department of Nuclear Medicine, Medical Faculty, Heinrich-Heine University, University Hospital Düsseldorf, Düsseldorf, Germany; and

15Institute for Radiation Sciences, Osaka University, Osaka, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 11

November 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Impact of ⁶⁸Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Journal of Nuclear Medicine Nov 2023, 64 (11) 1712-1720; DOI: 10.2967/jnumed.123.266046

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Impact of ⁶⁸Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Journal of Nuclear Medicine Nov 2023, 64 (11) 1712-1720; DOI: 10.2967/jnumed.123.266046

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors
Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions

Google Scholar

Keywords

FAPI
PET/CT
management
staging
radiation therapy

Main menu

User menu

Search

Impact of ⁶⁸Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords